THE TREATMENT OF THE CHRONIC INFLAMMATORY DISEASES OF INTESTINE WITH THE USE OF IMMUNOSUPRESSANT BIOLOGICAL DRUGS

Abstract


Prevalence, gravity of current, complexity of treatment of chronic inflammatory diseases of intestine - the illnesses of Crone and the ulcer of colitis - cause the value of this problem in modern gastroenterology. Despite of intensive researches, its pathogenesis remains not clear. It influences develop owing the combination of many negative factors at the leading part of the during the treatment of genetic factors and the factors of an environment.


V. J. Schwarz

Author for correspondence.
mail@exampl.com
Бад Колберг
Germany, Бамберг

A. M. Nogaller

mail@exampl.com

Germany

  • Newman B, Siminovitch KA. Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol. 2005; 21: 401-407.
  • Cashman KD, Shanahan F. Is nutrition an aetiological factor for inflammatory bowel disease? Eur J Gastroenter Hepatol. 2003; 15: 607-613.
  • Quelette AJ. Defensin-mediated innate immunity in the small intestine. Best Prac Res Clin Gastroenterol. 2004; 18: 405-419.
  • Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol. 2005; 21: 147-151.
  • Herrlinger K, Stange EF. Chroonisch-entzuendliche Darmerkrankungen – neue Therapieansaetze. Med Klein. 2008; 103: 90-101.
  • Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453-455.
  • Lemann M, et al. A randomized, double-blind, controlled withdrawal trial in Crohn´s disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128: 1812-1818.
  • Kozarek RA, et al. Methtrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353- 356.
  • D´Haens G, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antobodies in Crohn´s disease: a European multicenter trial. 1999. Gastroenterology; 116: 1029-1034.
  • Hommes DBF, Baert F, Van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn´s disease: top-down vs. step-up strategies. Gastroenterology. 2005; 128: A577.
  • Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Long-term evolution of disease behavior of Crohn´s disease. Inflamm Bowel Dis. 2002; 8: 244-250.
  • Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosupressants in Crohn´s disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
  • Baraliokos X, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-(alpha) antibody infliximab. Rheumatology (Oxf). 2007; 46: 1450-1453.
  • Baumgart DC, Tanczos BT, Dignass A. Therapie chronisch entzuendlicher Darmerkrankungen mit Biologika und Immunmdulatoren. DBI. 2006; 26: 144-146.
  • Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther. 2007; 7: 1051- 1059.
  • Targan SR, et al. A short-team study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn´s disease. Crohn´s Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
  • Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroiddependent Crohn´s disease patients: a randoized placebo-controlled trial. Gastroenterology. 2006; 130: 1054-1061.
  • Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn´s disease. Gastroenterology. 2004; 126: 402-413.
  • Present DH, et al. Infliximab for the treatment of fistulas in patients with Crohn´s disease. N Engl J Med. 1999; 340: 1398-1405.
  • Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulising Crohn´s disease. N Engl J Med. 2004; 350: 876-885.
  • Jarnerot G, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomoized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811.
  • Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
  • Ljung T, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm Country. Gut. 2004; 53: 849-853.
  • Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn´s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
  • Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person years of observation. Arthritis Rheum. 2007; 56: 1433-1439.
  • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serios infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275-2285.
  • Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn´s disease: the CLASSIC-1 trial. Gastroenterology. 2006; 130: 323-333.
  • Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn´s disease: resalts of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
  • Сolombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn´s disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
  • Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn´s disease previously treated with infliximab. A randomized trial. Ann Intern Med. 2007; 146: 829-838.
  • Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn´s disease. Gastroenterology. 2005; 129: 807-818.
  • Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintance therapie with certolizumab pegol for Crohn´s disease. N Engl J Med. 2007; 357:239-250.
  • Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical tials. Arthritis Rheum. 2006; 54: 3399-3407.
  • Schreiber S. Morbus Crohn – Infliximab, Adalimumab und Certolizumab-Pegol: Was bringen die neuen Gegenspieler des TNF-a? DMW. 2007; 132: 1770-1774.
  • Khanna D, McMahon M, Furst D. Safety of tumor necrosis factor alpha antagonists. Drug Safety. 2004; 34: 161-164.
  • American college of rheumatology: guidelines fort he management of rheumatoid arthritis. 2002, update. Arthritis Rheum. 2002; 46: 328-346.

Views

Abstract - 51

PDF (Russian) - 47


Copyright (c) 2017 Schwarz V.J., Nogaller A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.